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Abstract
Objective The objective was to evaluate the use of fluo-
rodeoxyglucose positron emission tomography (FDG-PET)
in differentiating benign from malignant compression
fractures.
Patients and methods In a retrospective analysis, we
identified 33 patients with 43 compression fractures who
underwent FDG-PET. On FDG-PET the uptake pattern was
recorded qualitatively and semiquantitatively and fractures
were categorized as benign or malignant. Standardized
uptake values (SUV) were obtained. MRI, CT, and biopsy
results as well as clinical follow-up for 1–3 years served as
standards of reference. The Student’s t test was used to
determine whether there was a statistically significant
difference between the SUV for benign and malignant
compression fractures.
Results There were 14 malignant and 29 benign compres-
sion fractures, including 5 acute benign fractures. On FDG-
PET, 5 benign fractures were falsely classified as malignant
(false-positive). Three of these patients underwent prior
treatment with bone marrow-stimulating agents. There were
two false-negative results. Sensitivity, specificity, positive
predictive value, negative predictive value, and accuracy
of FDG-PET in differentiating benign from malignant
compression fractures were 86%, 83%, 84%, 71%, and
92% respectively. The difference between SUV values of
benign and malignant fractures was statistically significant
(1.9±0.97 for benign and 3.9±1.52 for malignant fractures,
p<0.001). SUV of benign acute and chronic fractures were
not statistically significant.
Conclusion Fluorodeoxyglucose positron emission tomog-
raphy is useful in differentiating benign from malignant
compression fractures. Therapy with bone marrow-stimu-
lating agents can mimic malignant involvement.
Keywords Spine . Compression fractures . Malignant .
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Introduction
Differentiating between malignant and benign vertebral
compression fractures can represent a diagnostic challenge
and is particularly difficult in elderly patients, who
frequently have a history of malignancy and are also
predisposed to benign compression fractures from osteopo-
rosis or treatment-related changes [1–3]. Differentiating
between benign and malignant compression fractures has
important therapeutic and prognostic implications.
Computed tomography (CT) and magnetic resonance
imaging (MRI) are routinely used in the evaluation of
compression fractures; however, these imaging modalities
do not always permit definite diagnosis [2–5]. In contrast
to MRI or CT, fluorodeoxyglucose positron emission
tomography (FDG-PET) can yield metabolic information
that is based on increased glucose metabolism of malignant
and inflammatory lesions. Tumor cells typically accumu-
late FDG, while traumatic fractures are not expected
to significantly accumulate FDG. Therefore, FDG-PET
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may allow differentiation between malignant and benign
compression fractures [6–9].
The purpose of our study was to evaluate the use of
FDG-PET in differentiating benign from malignant com-
pression fractures.
Materials and methods
This study was approved by the institutional review board
of our institution, which waived the need for informed
consent. The study was compliant with the Health
Insurance Portability and Accountability Act. A retrospec-
tive search was performed using Boolean operators (Folio;
Open Market, Proto, UT, USA) to identify all patients who
had undergone whole-body FDG-PET at our institution
from 2003 to 2006 and had the finding of a compression
fracture mentioned in the PET report. Imaging studies and
reports, medical records, and pathology reports of selected
cases were reviewed.
Patients
We identified 33 patients with compression fractures who
underwent whole-body FDG-PET. There were 23 women
and 10 men, aged 48–93 years, with a mean age of 72 years.
Twenty-nine patients had a history of malignancy (1 had
leukemia, 5 lung cancer, 1 ovarian cancer, 2 breast cancer , 5
colon cancer, 9 lymphoma, 1 sarcoma, 1 pancreatic cancer, 1
Klatskin tumor, 1 gastrointestinal stromal tumor, 1 laryngeal
cancer, and 1 had esophageal cancer). The 4 patients without
history of malignancy underwent whole body PET for work-
up of indeterminate lung nodules detected on prior CT or
radiographs. Sixteen patients underwent FDG-PET and 17
patients underwent FDG-PET/CTat time of evaluation. Nine
patients underwent CTand 14 patients underwent MRI of the
Fig. 1 a Malignant compres-
sion fracture in a patient with
lymphoma. Sagittal FDG-PET
image demonstrates intense
radiotracer uptake in the L1
vertebral body (SUV=7.1;
arrow). b Axial FDG-PET
image demonstrates tumor infil-
tration of the L1 vertebral body
with associated extra-osseous
component (arrows). c Sagittal
T1-weighted MRI demonstrates
diffuse low signal intensity of
the bone marrow of the lumbar
spine with compression fracture
of L1 (arrow). d Sagittal fat-
suppressed T1-weighted MRI
following the administration of
gadolinium demonstrates diffuse
enhancement of the L1 com-
pression fracture (arrow).
e Axial image from a CT-guided
biopsy demonstrates large extra-
osseous soft tissue component
(white arrow) and infiltration of
the L1 vertebral body (black
arrows)
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spine within 4 weeks of FDG-PET. Seventeen patients were
followed up with serial FDG-PET studies. Nine patients
underwent biopsy and the pathologic results were used as
a standard of reference. Twenty-four patients who did
not undergo biopsy were followed up clinically and with
repeat imaging, with MRI, CT, or FDG-PET for a period of
1–3 years and findings at clinical follow-up and imaging
studies were used for lesion verification. In these patients,
the development of new lesions and/or progression of
existing lesions on imaging were used as criteria for
malignant compression fractures.
Image acquisition
Whole-body PET was performed using an ECAT HR+
scanner (CTI Molecular Imaging, Knoxville, TN, USA).
All patients fasted for at least 6 h prior to image acquisition,
and blood glucose levels were measured prior to the
injection of FDG. A dose of 15–20 mCi (555–740 MBq)
of FDG was administered intravenously 45 min to 1 h prior
to scanning.
Patients were positioned supine on the scanner and
emission images were acquired in 6–7 bed positions from the
Fig. 2 a Malignant compres-
sion fracture from metastatic
colon cancer. Sagittal fused
FDG-PET/CT image demon-
strates intense radiotracer uptake
in the T7 compression fracture
(SUV=6.3; arrow). b Axial
fused FDG-PET/CT image
demonstrates focal increased ra-
diotracer uptake in the T7 ver-
tebral body (arrow). c Sagittal
T1-weighted MRI demonstrates
compression fracture of T7 with
low signal marrow infiltration
(arrow). d Sagittal STIR image
demonstrates mild hyperinten-
sity of the T7 vertebral com-
pression fracture (arrow).
e Sagittal fat-suppressed T1-
weighted MRI following the
administration of gadolinium
demonstrates diffuse enhance-
ment of the T7 compression
fracture (arrow). Malignancy
was indeterminate on MRI
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mandible to the mid-thigh or to the level of the ankles in the
case of lower extremity lesions. Transmission images obtained
with a rotating germanium 68-rod source were used for
attenuation correction. Images were reconstructed using the
ordered-subset expectation maximization (OSEM) algorithm.
Combined PET/CT studies were performed with a 16-
section hybrid PET/CT gantry (Biograph Sensation 16;
Siemens, Erlangen, Germany), which comprises a 16-section
high-performance multi-detector row CT scanner with a
lutetium oxyorthosilicate-based PET scanner. The PET
image spatial resolution was 5.0 mm full width at half
maximum, with a section thickness of 3.5 mm. Patients
fasted for at least 6 h prior to image acquisition, and blood
glucose levels were measured prior to the injection of FDG.
Two 10-oz cups of water were administered as negative
contrast material 1 h prior to scanning. A dose of 15–20 mCi
(555–740 MBq) of FDG was administered intravenously
45 min to 1 h prior to scanning. Patients were positioned
supine on the scanner and emission images were acquired in
6–7 bed positions from the mandible to mid-thigh or to the
level of the ankles in the case of lower extremity lesions.
Images were reconstructed with Fourier rebinning and
attenuation-weighted ordered-subsets expectation maximi-
zation. A low-dose CT scan was performed prior to PET
imaging primarily for attenuation correction, with patients
holding their breath mid-expiration, and included an area
from the mandible to the mid-thigh or to the level of the
ankles in the case of lower extremity lesions. Slice thickness
was 5 mm. A diagnostic contrast-enhanced CT was
performed subsequent to the PET/CT following the admin-
istration of 100 mL intravenous contrast material (Isovue
300; Bracco Diagnostics, Princeton, NJ, USA) at an injection
rate of 2 mL/s using 2.5-mm sections.
Image analysis
Semiquantitative and qualitative evaluation of PET images
was performed on a high-resolution workstation (Reveal-
MVS; Mirada Solutions, Oxford, UK) by one investigator,
who was blinded to the clinical and pathological results
(MAB). The images were displayed in rotating maximum
intensity projections and in axial, coronal, and sagittal
planes. Semiquantitative analysis of FDG uptake was
Fig. 3 Benign compression fracture in a patient with lymphoma.
Sagittal fused FDG-PET/CT image demonstrates compression fracture
of T9 (arrow) without significant radiotracer uptake (SUV=0.7)
Fig. 4 a Benign subacute compression fractures in a patient without
history of malignancy. Sagittal FDG-PET image demonstrates mildly
increased radiotracer uptake in the upper thoracic spine (SUV=1.8;
arrow). b Axial FDG-PET image at the level of T4 demonstrates
mildly increased radiotracer uptake (arrow), consistent with subacute
compression fracture. c Sagittal CT image demonstrates compression
fracture of T4 (arrow) and multiple chronic osteoporotic compression
fractures throughout the thoracic spine
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performed by creating a region of interest over the area of
maximal radiotracer activity.
Maximum standardized uptake values (SUVs) were
automatically generated according to the following equation:
SUVmax (bw)=Ctis/Dinj/bw, where SUVmax (bw) is maximum
SUV normalized for body weight; Ctis, tissue concentration
expressed as megabecquerels per milliliter; Dinj, injected
dose expressed as megabecquerels; and bw, body weight
expressed as kilograms. Lesions with SUV greater than 3.0
were considered malignant and less then 3.0 were consid-
ered benign. However, lesions with SUV between 2 and 3
are often indeterminate and do not always allow definite
diagnosis, and also the pattern of uptake has to be
considered. Qualitative assessment was made with the
specific aim of establishing whether the lesion was benign
or malignant. The radiotracer uptake by the lesion was
compared with the liver, and those lesions with uptake
greater than the liver were classified as malignant.
Statistical analysis
The recorded data were analyzed using JMP statistical
database software (SAS Institute, Cary, NC, USA). The
findings on the PET images as well as SUV of benign and
malignant compression fractures were correlated with the
final diagnosis of the lesion and determined either malignant
Fig. 5 a False-negative compression fracture on FDG-PET in a
patient with metastatic esophageal cancer. Sagittal fused FDG-PET/
CT image demonstrates mild to moderately increased radiotracer
uptake in the L2 compression fracture (arrow; SUV=2.5) that was
thought to represent a benign compression fracture but was found to
be malignant on subsequent biopsy. Note the mildly increased
radiotracer uptake in the T11 compression fracture (arrowhead),
which was thought to represent a benign fracture. b Axial fused
FDG-PET/CT image demonstrates increased radiotracer uptake in
the L2 vertebral body (arrow). c Sagittal CT image demonstrates L2
and T11 compression fractures (arrows), for which malignancy was
indeterminate
Fig. 6 a False-positive compression fracture in a patient on bone
marrow-stimulating agents. Sagittal FDG-PET image demonstrates
diffuse increased radiotracer activity throughout the spine. Note the
compression fractures with focal kyphotic angulation at L1–L2
(arrow). The patient was thought to have diffuse metastatic disease
with malignant compression fracture. b Sagittal FDG-PET image
performed 2 months later demonstrates resolution of diffuse radiotracer
uptake. Kyphotic angulation from compression fractures remains
(arrow). The patient was off bone marrow-stimulating agents for
6 weeks at the time of the study
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or benign. Sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy were calculated. The
Student’s t test was used to determine whether there was a
statistically significant difference between the SUV for
benign and malignant compression fractures. A difference
with p<0.05 was considered to be statistically significant.
Results
Forty-three compression fractures were identified in 33
patients. Twenty-two fractures involved the thoracic and 21
fractures the lumbar spine. Nine patients underwent biopsy
and 24 patients were followed up clinically and with repeat
imaging. In the 9 patients who underwent biopsy, there
were 3 benign and 6 malignant compression fractures. Of
the 24 patients who were followed clinically and with
repeat imaging, 6 patients were thought to have malignant
and 18 patients were thought to have benign compression
fractures. Overall, there were 21 patients with benign and
12 patients with malignant compression fractures. Out of
the 43 compression fractures, there were 29 benign and 14
malignant fractures.
Based on clinical history (acute onset of back pain often
after minor trauma) and imaging characteristics on MRI
(bone marrow edema) there were 5 acute benign compression
fractures. Three patients were on bone marrow-stimulating
therapy at the time of FDG-PET. Five patients were unable to
undergo MRI because of pacemakers (3) or severe pain.
Qualitative PET analysis
Forty-three compression fractureswere identified in 33 patients.
Visual inspection of suspected lesions on FDG-PET charac-
terized 26 compression fractures as benign and 17 fractures
as malignant. The malignant lesions demonstrated intense
radiotracer uptake (Figs. 1, 2), while benign compression
fractures showed only mildly increased or no increased
uptake on FDG-PET (Figs. 3, 4). Histological and clinical
follow-up data were analyzed. By FDG-PET, 12 lesions were
correctly classified as malignant (true-positive) and 24
lesions were correctly classified as benign (true-negative).
Fig. 7 a False-positive com-
pression fracture in a patient
with laryngeal cancer. Sagittal
fused FDG-PET/CT image
demonstrates increased radio-
tracer uptake in the T12 com-
pression fracture (SUV=4.9;
arrow). b Sagittal T1-weighted
MRI demonstrates compression
fracture of T12 with linear low
signal of the superior endplate
and preservation of the normal
marrow signal (arrow). Note
compression fracture of L1 with
relative preservation of normal
marrow signal (arrowhead).
c Sagittal STIR image demon-
strates hyperintensity of the su-
perior endplates of the T12 and
L1 compression fractures, sug-
gesting acute fractures (arrows).
d Sagittal fat-suppressed T1-
weighted MRI following the
administration of gadolinium
demonstrates enhancement of
the T12 compression fracture
(arrow). Mild enhancement is
noted, involving the L1 com-
pression fracture (arrowhead).
Findings were thought to be
benign on MRI and on follow-
up imaging, there was resolution
of bone marrow edema and
enhancement
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Two malignant tumors were incorrectly classified as benign
(false-negative) and 5 benign tumors were incorrectly
classified as malignant (false-positive). In the 2 false-negative
cases there was moderately increased uptake of the compres-
sion fractures, which was thought to represent acute benign
fractures prospectively, but was found to be metastatic
disease on subsequent biopsy (Fig. 5). SUV in these patients
were 2.5 to 2.8 respectively, and the primaries in these cases
were esophageal and lung cancer.
Three of the false-positive patients were on bone marrow-
stimulating agents (Fig. 6). One of the false-positive patients
had an acute compression fracture (Fig. 7). Except for
that patient, there was no significant difference in uptake
pattern of benign acute and benign chronic compression
fractures (Fig. 8).
Quantitative PET analysis
Standardized uptake values were measured in all 43
compression fractures. SUV for benign compression frac-
tures ranged from 0.7 to 4.9 with a mean of 1.94±0.97
standard deviation (SD) on FDG-PET. Malignant compres-
sion fractures showed SUV from 2.2 to 7.1 with a mean of
3.99±1.52 SD on FDG-PET. The difference between the
SUV values of benign and malignant compression fractures
was statistically significant (p<0.001, Student’s t test;
Fig. 9).
Statistical analysis
Sensitivity, specificity, positive and negative predictive
values, and accuracy of FDG-PET in differentiating benign
from malignant compression fractures were 86%, 83%,
84%, 71%, and 92% respectively.
Discussion
The correct diagnosis of benign and malignant compression
fractures can be problematic, but has important prognostic
and therapeutic implications. MRI, CT, or bone scintigra-
phy are commonly used in the diagnostic work-up of
patients with compression fractures. However, in some
cases, these imaging techniques do not permit definite
diagnosis of the cause of the compression fracture.
Diffusion-weighted MRI has been used successfully to
differentiate benign from malignant fractures [10–13], but
benign and malignant compression fractures can show
Fig. 8 a Acute and chronic benign compression fractures in a patient
without history of malignancy. Sagittal fused FDG-PET/CT image
demonstrates multiple compression fractures throughout the thoracic
and lumbar spine with mild increased radiotracer uptake at T11 (SUV=
2.1; arrow). b Sagittal T1-weighted MRI demonstrates multiple chronic
compression fractures (arrowheads). Mild decreased signal intensity of
the T11 compression fracture suggests edema (arrow). c Sagittal STIR
image demonstrates mild edema in the T11 compression fracture
suggestive of an acute fracture (arrow). There is no evidence of marrow
edema in the remaining compression fractures
Fig. 9 Mean standardized uptake value (SUV) of benign and
malignant compression fractures. The top of the boxes represent the
mean and error bars represent the range of SUV. There is a statistically
significant difference between the SUV values of benign and those of
malignant compression fractures ( p<0.001, Student’s t test)
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significant overlap on quantitative assessment with appar-
ent diffusion coefficient maps [12]. Also, some patients
are unable to undergo MRI due to pacemakers, claus-
trophobia, or severe pain. This is especially true in the
elderly population. Five of our 33 patients were unable
to undergo MRI.
In this context, metabolic imaging modalities such as
FDG-PET might be used as a management problem solver.
FDG-PET has been successfully used to differentiate
benign from malignant neoplasms and in the evaluation of
metastatic disease [14–16]. Preliminary studies and case
reports have shown that FDG-PET might be helpful in
differentiating benign from malignant compression frac-
tures [8, 9]. Since elderly patients often have a history of
malignancy and are also predisposed to benign compression
fractures due to osteoporosis, we thought that FDG-PET
might be used as a diagnostic problem solver in this patient
population in cases of equivocal MRI or CT findings or if
the patient was unable to undergo MRI.
In our study, malignant compression fractures demon-
strated significantly increased FDG uptake compared with
benign fractures. Mean SUV of malignant and benign
fractures were 3.99±1.52 SD for malignant lesions and
1.94±0.97 SD for benign lesions. There were 2 false-
negative results. In these cases there was moderately
increased uptake of the compression fractures, which were
thought to be acute benign fractures prospectively, but were
found to represent metastatic disease on subsequent biopsy.
SUV in these patients were 2.5 to 2.8 respectively.
There were 5 false-positive results; 3 of those patients
were on bone marrow-stimulating agents, which mimicked
tumor involvement. This effect on bone marrow FDG
uptake has been described in the literature [17]. One to
2 months after cessation of bone marrow-stimulating
therapy, FDG uptake returned to normal in our patients.
The false-positive results occurred because the investigator
was blinded to the clinical history. This is less likely to
occur in a clinical setting where this history should be
actively sought when interpreting positive findings, espe-
cially in cases of diffuse osseous uptake, mimicking a
diffuse marrow infiltrative process as was seen in our cases.
In fact, when we reviewed the original reports, these cases
were reported to be consistent with the known use of bone
marrow-stimulating agents.
Only mildly increased or no increased uptake was seen
in chronic benign fractures and mild to moderately
increased uptake was seen in acute benign fractures, which
was less than in malignant fractures. This is in contrast to
bone scintigraphy, in which increased uptake persists for
many months [18].
Positron emission tomography and PET/CT were equally
sensitive in differentiating benign from malignant compres-
sion fractures. However, the CT portion of the PET/CT
improved the exact fracture localization and was able to
provide additional information on fracturemorphology, which
can be helpful in diagnosing benign vs. malignant fractures.
Our study had several limitations. The first is the
retrospective nature of the study. Second is the lack of
histologic correlation in all cases. Only 9 patients under-
went biopsy of the spine. However, we obtained clinical
follow-up and serial imaging studies, including serial FDG-
PET for a period of 1–3 years to evaluate for benign or
malignant fractures. Also, there were no patients with
osteomyelitis/discitis, which can mimic malignancy [8, 19,
20]. Another limitation is the lack of inter-observer
variability, since only one observer interpreted the images.
However, we compared our results with the reports of the
original interpreter, who had access to all data. On the
original reports, the 3 cases of patients on bone marrow-
stimulating agents were interpreted as being consistent with
the known use of bone marrow-stimulating agents. Malig-
nancy was said to be indeterminate in the two false-
negative reports. However, in our review, we categorized
each fracture as either benign or malignant without the
option of an indeterminate lesion.
In summary, FDG-PET is a useful method of differen-
tiating between benign and malignant compression frac-
tures and can serve as a problem solver in cases of
equivocal MRI or CT findings, and in patients who are
unable to undergo MRI. We do not recommend FDG-PET
as a screening test, but rather as an additional imaging
modality in problem cases, particularly in elderly patients
with osteoporosis and a history of malignancy. In these
patients, FDG-PET has the additional advantage of being
able to evaluate the entire skeletal system and screen for
metastatic disease.
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